The medication is applied across therapeutic domains including the management of Hypertension and Coronary Artery Disease (CAD). It is utilized to help with symptoms related to systemic imbalance and heightened physiological activity across these core domains.

---

Sustained Treatment for Persistent High Blood Pressure

The primary therapeutic objective involves long-term cardiovascular support, relevant to the management of persistently elevated systemic pressure. The medicine is primarily used to address the chronic condition of Hypertension in adults and is considered relevant for use in pediatric patients aged 6 to 17 years. This supports a positive change in systemic imbalance and may assist with managing risk factors associated with cardiovascular events.

Management of Chronic Angina and Chest Pain Symptoms

Amlodipin Genericon generally provides therapeutic support for patients with Angina Pectoris, including both predictable Chronic Stable Angina and the spasm-driven Vasospastic Angina. It supports the management of symptoms that create noticeable physiological strain, which may assist with easing the burden of episodic chest discomfort.

---

Quick Fact: Relevant for Episodic Chest Discomfort

Eligibility Map: Who can and cannot use Amlodipin Genericon — Official Regulatory Information

Eligibility scope

• Populations for whom use is allowed (as stated in label): Adults are eligible for all approved uses. Pediatric patients aged 6 to 17 years are eligible for the treatment of hypertension only.
• Populations for whom use is not recommended (if applicable): Use is not recommended in children under 6 years of age due to lack of established safety data. Use during pregnancy or while breastfeeding is generally not recommended, as defined in official regulatory documents.
• Populations for whom use is contraindicated: Absolute contraindications include known hypersensitivity to amlodipine or dihydropyridines, severe hypotension, all forms of shock (including cardiogenic shock), obstruction of the left ventricular outflow tract (e.g., severe aortic stenosis), and haemodynamically unstable heart failure after a recent heart attack.
• Age-related eligibility rules: Older adults are eligible, but caution is advised when increasing the dosage. Children under 6 years are not eligible.
• Condition-specific eligibility rules: Use requires caution in patients with impaired liver function due to the drug's prolonged half-life. Caution is also advised for patients with heart failure. Use in patients with renal impairment typically requires no initial dose adjustment.
• Pregnancy and lactation eligibility status (if explicitly documented): Use during pregnancy is only recommended when no safer alternative is available. Use while lactation is generally not recommended.
• Eligibility-related restrictions: The use in pediatric patients (6–17 years) is restricted to the treatment of hypertension.

Connection to the overall eligibility profile

The regulatory profile strictly defines eligibility by establishing absolute contraindications based on severe cardiovascular states and hypersensitivity. It mandates caution for populations with compromised organ function, such as hepatic impairment, and for those with pre-existing heart failure. Furthermore, it limits approved use by age, restricting treatment in children under six years and setting specific rules for pediatric hypertension.

Interactions with other medicines and products

This section describes the interactions of Amlodipin Genericon (Amlodipine) as officially documented in government regulatory labeling.

Amlodipine Exposure Modification

Amlodipine is metabolized by the CYP3A4 enzyme. Co-administration with strong or moderate CYP3A4 inhibitors (such as certain macrolide antibiotics, antifungals, and protease inhibitors) results in increased systemic exposure to Amlodipine, which may increase the risk of hypotension. Conversely, strong CYP3A4 inducers (such as Rifampicin or St John's Wort) may reduce Amlodipine's plasma concentration; blood pressure monitoring is necessary when co-administered.

Interactions Affecting Other Medicines

Amlodipine significantly increases the systemic exposure of the cholesterol-lowering agent Simvastatin. Regulatory requirements state that the dose of Simvastatin must be limited to a maximum of 20 mg daily when co-administered with Amlodipine. The blood levels of immunosuppressants such as Cyclosporine and Tacrolimus may also be increased by Amlodipine, and their blood levels should be monitored.

Pharmacodynamic and Specific Restrictions

Substance / Category	Official Restriction / Effect
Other Antihypertensives	Additive antihypertensive effect, potentially leading to increased hypotension [Source 2.2].
Dantrolene (Intravenous)	Co-administration is generally avoided in patients susceptible to malignant hyperthermia due to risk of hyperkalemia [Source 2.4].
Grapefruit / Grapefruit Juice	Not recommended as it may increase Amlodipine bioavailability [Source 2.4].
Aliskiren-containing products	Formally contraindicated in patients with diabetes mellitus (based on combination product labeling) [Source 2.2].

Mechanism of Action: Calcium Channel Antagonism

Amlodipine functions as an antagonist of Voltage-Dependent L-type Calcium Channels (LTCCs), which are predominantly situated in the cell membranes of vascular smooth muscle tissue. The molecule binds to these channels, inhibiting the influx of extracellular calcium ions (Ca^2+) into the cell's cytosol. This inhibition directly interrupts the excitation-contraction coupling cascade within the muscle fiber, as the reduced intracellular calcium prevents the activation of proteins required for the actin-myosin cross-bridge formation.

The resulting collective relaxation of the smooth muscle cells leads to arterial vasodilation—a widening of the peripheral blood vessels. This vasodilation initiates a subsequent cascade at the systemic level, reducing the overall resistance to blood flow, defined as Total Peripheral Resistance (TPR). The reduction in TPR is the core physiological adjustment that results in a decrease in arterial pressure. The mechanism exhibits a greater affinity for vascular LTCCs than for cardiac LTCCs, ensuring the primary effect is peripheral vascular modulation.

Official Administration Guidelines

Amlodipin Genericon is intended for oral administration as a single-ingredient tablet, available in 2.5 mg, 5 mg, and 10 mg strengths. The medicine is taken once daily to support long-term, continuous therapy, maintaining consistent levels in the body.

Indication	Initial Dose (Adults)	Maximum Dose (Adults)
Hypertension	5 mg once daily	10 mg once daily
Angina/CAD	5 mg once daily	10 mg once daily

Dosing Schedules and Titration

For most adult patients, the usual initial dose for hypertension is 5 mg once daily, which may be increased up to a maximum of 10 mg daily. Dosage adjustment, or titration, should generally proceed slowly, with a waiting period of 7 to 14 days between increases to fully assess the effect of the current dose. The total daily dose should never exceed 10 mg.

Specific Patient Populations and Intake

Lower starting doses of 2.5 mg once daily are advised for older adults and patients with hepatic impairment, reflecting a need for cautious, slow titration in these groups. For pediatric patients aged 6 to 17 years with hypertension, the dose range is 2.5 mg to 5 mg once daily, with 5 mg being the maximum studied dose. The tablet can be taken with or without food and should be consumed at approximately the same time each day. If a dose is missed, it should be taken as soon as the lapse is noticed on that day, but a double dose must never be taken to compensate for a forgotten one.

Research evidence / Overview of studies for Amlodipin Genericon

Evidence for use in High Blood Pressure (Hypertension)

The research base for Amlodipine's use in managing persistently elevated blood pressure is largely supported by extensive, long-term Randomized Controlled Trials (RCTs) and systematic Meta-analyses. These studies were designed to explore how Amlodipine compares against inactive placebo and against other established classes of high blood pressure medicines. Researchers in these pivotal trials primarily focused on measuring changes in both the upper and lower numbers of blood pressure (systolic and diastolic BP). The long-term studies also monitored important outcomes related to systemic or functional imbalance, specifically tracking the occurrence of major Cardiovascular Events, including heart attacks (myocardial infarction) and stroke, during the study duration.

Findings describe patterns observed in these large-scale studies, indicating measured changes in the blood pressure levels of the observed populations. Research highlights that studies reported how BP levels evolved in the observed populations, and trials reported measurements that allowed researchers to follow patients for several years. Findings helped contextualize how this approach was observed in different patient groups. Certain studies were also applied in research contexts involving fluctuating or unstable symptoms where BP was measured throughout a 24-hour period.

Evidence for use in Coronary Artery Disease and Angina

The evidence for Amlodipine's use in managing chest pain symptoms associated with coronary artery disease (CAD) relies on Placebo-controlled RCTs and trials that compared it against other established antianginal treatments. Research examined outcomes related to physical discomfort and outcomes describing episodic or acute changes, focusing on the frequency of patient-reported Angina Episodes and their reliance on acute pain relief medicine. Researchers also monitored functional outcomes by measuring changes in a patient's Exercise Tolerance and tracking the incidence of hospitalization for angina.

Findings describe patterns observed during the study period, including measurements related to the frequency of patient-reported chest discomfort. Studies explored how symptoms evolved in patients with both stable, predictable angina and the spasm-driven variant (vasospastic angina). Research describes symptom patterns in conditions characterized by fluctuating or episodic manifestations.

What is Still Uncertain About the Research Base

While the evidence base for Amlodipine is extensive for its core uses, the research highlights what is known and what is still uncertain. The available comparative evidence is lacking in head-to-head trials against every single newer generation of blood pressure or angina medication. Follow-up durations were limited in specific studies, meaning there is limited information for long-term outcomes extending beyond the trial environment. Evidence quality varies across studies, and findings describe group patterns, not personal outcomes, meaning research does not determine whether an individual will respond similarly.

Common questions about Amlodipin Genericon (FAQ)

Q: What is Amlodipin Genericon and what is it used for?

Amlodipin Genericon contains the active substance amlodipine, which belongs to a group of medicines called calcium channel blockers. It is used to treat:

• High blood pressure (hypertension): Amlodipine works by relaxing blood vessels, making it easier for blood to pass through and lowering blood pressure.
• A certain type of chest pain (angina pectoris): This includes a rare form called Prinzmetal's or variant angina. Amlodipine works by improving the blood and oxygen supply to the heart muscle.

---

Q: How does Amlodipin Genericon work?

Amlodipine is a calcium channel blocker. It works by blocking the movement of calcium into the muscle cells of the heart and blood vessels. Muscle cells need calcium to contract. By blocking this, amlodipine causes the muscle cells in the walls of the blood vessels to relax. This relaxation widens the blood vessels, which in turn lowers blood pressure and makes it easier for the heart to pump blood around the body. For angina, this widened blood flow increases the supply of oxygen to the heart muscle.

---

Q: Can Amlodipin Genericon be taken with food?

Amlodipin Genericon tablets can be taken with or without food and drink. They should be swallowed whole with a glass of water.

---

Q: What are the most common side effects of Amlodipin Genericon?

The most common side effect reported is edema (swelling), particularly of the ankles or feet. Other common side effects may include:

• Headache
• Dizziness, especially when standing up quickly
• Fatigue or drowsiness
• Flushing of the face and neck
• Palpitations (awareness of your heartbeat)
• Nausea and abdominal pain

These common side effects are often mild and may lessen over time as your body adjusts to the medicine.

---

Q: What should I do if I forget to take a dose of Amlodipin Genericon?

If you forget to take your dose, you should take it as soon as you remember. However, if it is already time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a forgotten tablet.

---

Q: Is Amlodipin Genericon safe for long-term use?

Amlodipine is generally considered safe and effective for long-term treatment of high blood pressure and angina. It is often necessary to take it continuously to keep blood pressure and chest pain under control. Your doctor will regularly assess your condition and the need for continued treatment.

How to Store and Dispose of Amlodipin Genericon

Official regulatory guidelines define specific requirements for the storage and final disposal of this medicine to ensure stability and environmental protection.

Storage and Handling Requirements

Requirement	Official Statement
Temperature	No special storage conditions are required.
Protection	Keep the tablets in the original carton and blister packaging to protect the product from light and moisture.
Child Safety	Mandatory to keep this medicine out of the sight and reach of children.

Disposal Rules

Regulatory documents stipulate that unused or expired Amlodipin Genericon must not be disposed of via household waste or wastewater. The active substance is classified as very toxic to aquatic life, meaning disposal must follow local pharmaceutical waste guidelines, such as utilizing a pharmacy take-back program or an approved collection point. This is necessary to prevent environmental contamination.